ATE170082T1 - Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen - Google Patents
Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilenInfo
- Publication number
- ATE170082T1 ATE170082T1 AT95117465T AT95117465T ATE170082T1 AT E170082 T1 ATE170082 T1 AT E170082T1 AT 95117465 T AT95117465 T AT 95117465T AT 95117465 T AT95117465 T AT 95117465T AT E170082 T1 ATE170082 T1 AT E170082T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- growth
- inhibiting
- cells
- leukemic cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33760594A | 1994-11-10 | 1994-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE170082T1 true ATE170082T1 (de) | 1998-09-15 |
Family
ID=23321225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95117465T ATE170082T1 (de) | 1994-11-10 | 1995-11-07 | Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0711565B1 (de) |
| AT (1) | ATE170082T1 (de) |
| DE (1) | DE69504278T2 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| PL202369B1 (pl) | 1999-08-27 | 2009-06-30 | Genentech Inc | Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało |
| CA2383615A1 (en) * | 1999-09-22 | 2001-03-29 | Corixa Corporation | Methods for diagnosis and therapy of hematological and virus-associated malignancies |
| CN1447696A (zh) | 2000-05-19 | 2003-10-08 | 杰南技术公司 | 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
| WO2002013847A2 (en) * | 2000-08-14 | 2002-02-21 | Corixa Corporation | Methods for diagnosis and therapy of hematological and virus-associated malignancies |
| ES2710439T3 (es) | 2005-01-21 | 2019-04-25 | Genentech Inc | Dosificación fija de anticuerpos HER |
| KR101253576B1 (ko) | 2005-02-23 | 2013-04-11 | 제넨테크, 인크. | Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장 |
| EP2899541A1 (de) | 2007-03-02 | 2015-07-29 | Genentech, Inc. | Voraussage der Reaktion auf einen HRE-Dimerisationshemmer auf Basis niedriger HER3-Expression |
| CA2690334C (en) | 2007-06-08 | 2017-02-14 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| AU2009308707A1 (en) * | 2008-10-31 | 2010-05-06 | Biogen Idec Ma Inc. | LIGHT targeting molecules and uses thereof |
| SG10201402742YA (en) | 2009-03-20 | 2014-08-28 | Genentech Inc | Bispecific anti-her antibodies |
| JP5705836B2 (ja) | 2009-05-29 | 2015-04-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター |
| KR20130000384A (ko) | 2010-02-18 | 2013-01-02 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 뉴레귤린 길항제 및 암의 치료에서의 그의 용도 |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| US20130245233A1 (en) | 2010-11-24 | 2013-09-19 | Ming Lei | Multispecific Molecules |
| JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
| US20140363438A1 (en) | 2011-08-17 | 2014-12-11 | Genentech, Inc. | Neuregulin antibodies and uses thereof |
| US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
| AU2012346540C1 (en) | 2011-11-30 | 2019-07-04 | Genentech, Inc. | ErbB3 mutations in cancer |
| WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| RU2014136886A (ru) | 2012-03-27 | 2016-05-20 | Дженентек, Инк. | Диагностика и виды лечения, связанные с ингибиторами her3 |
| JP6998646B2 (ja) | 2012-11-30 | 2022-02-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定 |
| WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
-
1995
- 1995-11-07 EP EP95117465A patent/EP0711565B1/de not_active Expired - Lifetime
- 1995-11-07 AT AT95117465T patent/ATE170082T1/de not_active IP Right Cessation
- 1995-11-07 DE DE69504278T patent/DE69504278T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0711565B1 (de) | 1998-08-26 |
| EP0711565A1 (de) | 1996-05-15 |
| DE69504278D1 (de) | 1998-10-01 |
| DE69504278T2 (de) | 1999-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69504278D1 (de) | Verfahren zur Wachstumshemmung von Leukämischen Zellen durch HER-2-Protein-Zeilen | |
| DE60330390D1 (de) | G-csf zur behandlung von amyotropher lateralsklerose | |
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| DE69508192D1 (de) | Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen | |
| ATE402698T1 (de) | Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten | |
| DE69809898D1 (de) | Zusammensetzung und verfahren zur behandlung von pflanzen mit exogenen chemikalien | |
| ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| TW200502385A (en) | Modulation of forkhead box o1a expression | |
| DE69523074D1 (de) | Verfahren zur behandlung von implantierbaren biologischen geweben zur verringerung von verkalkung | |
| ATE465261T1 (de) | Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken | |
| ATE526980T1 (de) | Zusammensetzungen und verfahren zur heilung von nervengeweben | |
| DE69622989D1 (de) | Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten | |
| DE60015791D1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| DE60111620D1 (de) | Aktiviertes protein c zur behandlung von pankreatitis | |
| DE69619187D1 (de) | Verfahren zur behandlung von motorischen defiziten | |
| ATE331799T1 (de) | Verfahren zur inhibierung der transkription von genen | |
| ATE203271T1 (de) | Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung | |
| ATE251462T1 (de) | Verfahren zur behandlung von narbengewebe | |
| ATE288498T1 (de) | Methoden zur inhibierung von helicobacter pylori | |
| ATE203162T1 (de) | Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one | |
| DE60034110D1 (de) | Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien | |
| ATE438859T1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
| ATE325812T1 (de) | Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors | |
| ATE311901T1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten | |
| ATE320263T1 (de) | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |